LENZ Therapeutics (GRPH) Stock Forecast, Price Target & Predictions
GRPH Stock Forecast
LENZ Therapeutics stock forecast is as follows: an average price target of $4.00 (represents a -82.03% downside from GRPH’s last price of $22.26) and a rating consensus of 'Hold', based on 4 wall street analysts offering a 1-year stock forecast.
GRPH Price Target
The average price target for LENZ Therapeutics (GRPH) is $4.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $7.00 to $2.00. This represents a potential -82.03% downside from GRPH's last price of $22.26.
GRPH Analyst Ratings
According to 4 Wall Street analysts, LENZ Therapeutics's rating consensus is 'Hold'. The analyst rating breakdown for GRPH stock is 0 'Strong Buy' (0.00%), 0 'Buy' (0.00%), 4 'Hold' (100.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
LENZ Therapeutics Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Feb 03, 2023 | - | Morgan Stanley | $3.00 | $2.18 | 37.61% | -86.52% |
| Jan 06, 2023 | - | RBC Capital | $4.00 | $3.06 | 30.72% | -82.03% |
| Jan 06, 2023 | - | Leerink Partners | $2.00 | $3.06 | -34.64% | -91.02% |
| Jan 06, 2023 | - | BMO Capital | $7.00 | $3.06 | 128.76% | -68.55% |
| Jul 15, 2022 | - | Morgan Stanley | $6.00 | $3.30 | 81.82% | -73.05% |
The latest LENZ Therapeutics stock forecast, released on Feb 03, 2023 by Morgan Stanley company, set a price target of $3.00, which represents a 37.61% increase from the stock price at the time of the forecast ($2.18), and a -86.52% decrease from GRPH last price ($22.26).
LENZ Therapeutics Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $22.26 | $22.26 | $22.26 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of LENZ Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to LENZ Therapeutics's last price of $22.26. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Feb 03, 2023 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Jan 06, 2023 | RBC Capital | Sector Perform | Sector Perform | Hold |
| Jan 06, 2023 | SVB Leerink | - | Market Perform | Downgrade |
| Jan 06, 2023 | BMO Capital | Outperform | Market Perform | Downgrade |
| Jul 15, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| Jun 17, 2022 | BMO Capital | - | Outperform | Initialise |
| Feb 18, 2022 | RBC Capital | - | Sector Perform | Initialise |
LENZ Therapeutics's last stock rating was published by Morgan Stanley on Feb 03, 2023. The company gave GRPH a "Equal-Weight" rating, the same as its previous rate.
LENZ Therapeutics Financial Forecast
LENZ Therapeutics Revenue Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
|---|---|---|---|---|
| Revenue | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| # Analysts | - | - | - | 1 |
| Surprise % | - | - | - | - |
LENZ Therapeutics's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. GRPH's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
LENZ Therapeutics EBITDA Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | 1 |
| EBITDA | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| Surprise % | - | - | - | - |
undefined analysts predict GRPH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than LENZ Therapeutics's previous annual EBITDA (undefined) of $NaN.
LENZ Therapeutics Net Income Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | 1 |
| Net Income | - | - | - | - |
| Avg Forecast | $-424.58K | $-424.58K | $-471.76K | $-518.94K |
| High Forecast | $-424.58K | $-424.58K | $-471.76K | $-518.94K |
| Low Forecast | $-424.58K | $-424.58K | $-471.76K | $-518.94K |
| Surprise % | - | - | - | - |
LENZ Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GRPH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
LENZ Therapeutics SG&A Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | 1 |
| SG&A | - | - | - | - |
| Avg Forecast | - | - | - | - |
| High Forecast | - | - | - | - |
| Low Forecast | - | - | - | - |
| Surprise % | - | - | - | - |
LENZ Therapeutics's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to GRPH last annual SG&A of $NaN (undefined).
LENZ Therapeutics EPS Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | |
|---|---|---|---|---|
| # Analysts | - | - | - | 1 |
| EPS | - | - | - | - |
| Avg Forecast | $-0.09 | $-0.09 | $-0.10 | $-0.11 |
| High Forecast | $-0.09 | $-0.09 | $-0.10 | $-0.11 |
| Low Forecast | $-0.09 | $-0.09 | $-0.10 | $-0.11 |
| Surprise % | - | - | - | - |
According to undefined Wall Street analysts, LENZ Therapeutics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GRPH previous annual EPS of $NaN (undefined).
LENZ Therapeutics Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| SNSE | Sensei Biotherapeutics | $0.54 | $5.50 | 918.52% | Buy |
| CTMX | CytomX Therapeutics | $1.23 | $5.77 | 369.11% | Buy |
| ACHL | Achilles Therapeutics | $0.72 | $2.00 | 177.78% | Buy |
| NUVB | Nuvation Bio | $3.05 | $7.00 | 129.51% | Buy |
| NXTC | NextCure | $1.40 | $3.00 | 114.29% | Buy |
| GRPH | LENZ Therapeutics | $3.18 | $4.00 | 25.79% | Hold |
| TIL | Instil Bio | $84.52 | $17.67 | -79.09% | Hold |
GRPH Forecast FAQ
Is LENZ Therapeutics a good buy?
No, according to 4 Wall Street analysts, LENZ Therapeutics (GRPH) is considered a 'Hold'. The rating consensus is based on 0 'Strong Buy' and 0 'Buy' recommendations, accounting for 0% of GRPH's total ratings.
What is GRPH's price target?
LENZ Therapeutics (GRPH) average price target is $4 with a range of $2 to $7, implying a -82.03% from its last price of $22.26. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will LENZ Therapeutics stock go up soon?
According to Wall Street analysts' prediction for GRPH stock, the company can go down by -82.03% (from the last price of $22.26 to the average price target of $4), down by -68.55% based on the highest stock price target, and down by -91.02% based on the lowest stock price target.
Can LENZ Therapeutics stock reach $30?
GRPH's average twelve months analyst stock price target of $4 does not support the claim that LENZ Therapeutics can reach $30 in the near future.
What are LENZ Therapeutics's analysts' financial forecasts?
GRPH's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-1.84M (high $-1.84M, low $-1.84M), average SG&A $0 (high $0, low $0), and average EPS is $-0.39 (high $-0.39, low $-0.39).